P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
J.-Z. Hou,
N. G. Daver,
D. A. Stevens,
T. Yamauchi,
Y. Moshe,
C. Y. Fong,
A. Marzocchetti,
R. Adamec,
M. Patel,
S. Lambert,
K. Y. Wu,
C. Röllig
Affiliations
J.-Z. Hou
1 UPMC Hillman Cancer Center, Pittsburgh, PA
N. G. Daver
2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
D. A. Stevens
3 Norton Cancer Institute, Louisville, KY, United States of America
T. Yamauchi
4 University of Fukui Hospital, Fukui, Japan
Y. Moshe
5 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
C. Y. Fong
6 Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
A. Marzocchetti
7 AbbVie S.r.l., Rome, Italy
R. Adamec
8 AbbVie Inc., North Chicago, IL
M. Patel
8 AbbVie Inc., North Chicago, IL
S. Lambert
9 AbbVie Inc., South San Francisco, CA, United States of America
K. Y. Wu
8 AbbVie Inc., North Chicago, IL
C. Röllig
10 Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany
